4161 Stock Overview
Engages in the production and sale of medical devices and reagents worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Bioptik Technology Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$32.70 |
| 52 Week High | NT$39.55 |
| 52 Week Low | NT$27.50 |
| Beta | 0.30 |
| 11 Month Change | -6.70% |
| 3 Month Change | -2.97% |
| 1 Year Change | 9.00% |
| 33 Year Change | 22.63% |
| 5 Year Change | -14.16% |
| Change since IPO | -6.56% |
Recent News & Updates
Shareholder Returns
| 4161 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -0.9% | 0.5% | 0.8% |
| 1Y | 9.0% | 0.7% | 30.3% |
Return vs Industry: 4161 exceeded the TW Medical Equipment industry which returned 0.7% over the past year.
Return vs Market: 4161 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 4161 volatility | |
|---|---|
| 4161 Average Weekly Movement | 3.4% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4161 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4161's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | n/a | www.bioptik.com.tw |
Bioptik Technology Incorporation engages in the production and sale of medical devices and reagents worldwide. It offers EasyMate blood glucose monitoring systems; blood glucose/cholesterol/uric acid monitoring systems and its strips; and hyaluronic acid skin care products. The company also provides skin care products and dietary supplements, as well as biodiesel products.
Bioptik Technology Incorporation Fundamentals Summary
| 4161 fundamental statistics | |
|---|---|
| Market cap | NT$1.73b |
| Earnings (TTM) | NT$99.69m |
| Revenue (TTM) | NT$884.11m |
17.4x
P/E Ratio2.0x
P/S RatioIs 4161 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4161 income statement (TTM) | |
|---|---|
| Revenue | NT$884.11m |
| Cost of Revenue | NT$611.06m |
| Gross Profit | NT$273.05m |
| Other Expenses | NT$173.36m |
| Earnings | NT$99.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.88 |
| Gross Margin | 30.88% |
| Net Profit Margin | 11.28% |
| Debt/Equity Ratio | 49.5% |
How did 4161 perform over the long term?
See historical performance and comparison